Do cardioselective β-adrenoceptor antagonists reduce mortality in diabetic patients with congestive heart failure?

Usha Subramanian, Masoor Kamalesh, M'Hamed Temkit, George J. Eckert, Stephen Sawada

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: The relative benefits of cardioselective β-adrenoceptor antagonists (CSB) among patients with congestive heart failure (CHF) and diabetes mellitus are not firmly established. Objective: To determine whether diabetic patients with CHF accrue the same mortality benefit from CSB therapy as non-diabetic patients. Methods: Between October 1999 and November 2000 consecutive patients with CHF at the Veteran?s Affairs Medical Center in Indianapolis, IN, USA, were enrolled in a randomized controlled trial and prospectively followed for 5 years. Disease severity and CHF-specific functional status were obtained from patients at baseline. Medical records were accessed for data regarding co-morbidities, medications, and mortality. Propensity- score analysiswas used to balance co-variates because of the observational nature of CSB use, given this was a post hoc analysis. A multivariate Cox proportional hazards model was used to compare survival between diabetic and non-diabetic patients stratified by whether they were or were not receiving CSB therapy. Results: Of the 412 evaluable patients, 222 (54%) had diabetes and 212 (51%) were taking a CSB. At 5-year follow-up, 186 (45%) patients had died. In the multivariate analysis, using propensity scores to balance covariates, CSB therapy was an independent predictor of survival in patients without diabetes (hazard ratio 0.60; p = 0.054) only. Conclusions: These results extend prior observations that patients with diabetes andCHFmay not accrue the same mortality benefit from CSB therapy as patients without diabetes, and warrant further prospective investigation.

Original languageEnglish (US)
Pages (from-to)231-240
Number of pages10
JournalAmerican Journal of Cardiovascular Drugs
Volume9
Issue number4
DOIs
StatePublished - Sep 21 2009

Fingerprint

Adrenergic Receptors
Heart Failure
Mortality
Propensity Score
Survival
Veterans
Therapeutics
Proportional Hazards Models
Medical Records
Diabetes Mellitus
Multivariate Analysis
Randomized Controlled Trials
Morbidity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Do cardioselective β-adrenoceptor antagonists reduce mortality in diabetic patients with congestive heart failure? / Subramanian, Usha; Kamalesh, Masoor; Temkit, M'Hamed; Eckert, George J.; Sawada, Stephen.

In: American Journal of Cardiovascular Drugs, Vol. 9, No. 4, 21.09.2009, p. 231-240.

Research output: Contribution to journalArticle

@article{153af193afbf4cedb42c227984288534,
title = "Do cardioselective β-adrenoceptor antagonists reduce mortality in diabetic patients with congestive heart failure?",
abstract = "Background: The relative benefits of cardioselective β-adrenoceptor antagonists (CSB) among patients with congestive heart failure (CHF) and diabetes mellitus are not firmly established. Objective: To determine whether diabetic patients with CHF accrue the same mortality benefit from CSB therapy as non-diabetic patients. Methods: Between October 1999 and November 2000 consecutive patients with CHF at the Veteran?s Affairs Medical Center in Indianapolis, IN, USA, were enrolled in a randomized controlled trial and prospectively followed for 5 years. Disease severity and CHF-specific functional status were obtained from patients at baseline. Medical records were accessed for data regarding co-morbidities, medications, and mortality. Propensity- score analysiswas used to balance co-variates because of the observational nature of CSB use, given this was a post hoc analysis. A multivariate Cox proportional hazards model was used to compare survival between diabetic and non-diabetic patients stratified by whether they were or were not receiving CSB therapy. Results: Of the 412 evaluable patients, 222 (54{\%}) had diabetes and 212 (51{\%}) were taking a CSB. At 5-year follow-up, 186 (45{\%}) patients had died. In the multivariate analysis, using propensity scores to balance covariates, CSB therapy was an independent predictor of survival in patients without diabetes (hazard ratio 0.60; p = 0.054) only. Conclusions: These results extend prior observations that patients with diabetes andCHFmay not accrue the same mortality benefit from CSB therapy as patients without diabetes, and warrant further prospective investigation.",
author = "Usha Subramanian and Masoor Kamalesh and M'Hamed Temkit and Eckert, {George J.} and Stephen Sawada",
year = "2009",
month = "9",
day = "21",
doi = "10.2165/1006180-000000000-00000",
language = "English (US)",
volume = "9",
pages = "231--240",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Do cardioselective β-adrenoceptor antagonists reduce mortality in diabetic patients with congestive heart failure?

AU - Subramanian, Usha

AU - Kamalesh, Masoor

AU - Temkit, M'Hamed

AU - Eckert, George J.

AU - Sawada, Stephen

PY - 2009/9/21

Y1 - 2009/9/21

N2 - Background: The relative benefits of cardioselective β-adrenoceptor antagonists (CSB) among patients with congestive heart failure (CHF) and diabetes mellitus are not firmly established. Objective: To determine whether diabetic patients with CHF accrue the same mortality benefit from CSB therapy as non-diabetic patients. Methods: Between October 1999 and November 2000 consecutive patients with CHF at the Veteran?s Affairs Medical Center in Indianapolis, IN, USA, were enrolled in a randomized controlled trial and prospectively followed for 5 years. Disease severity and CHF-specific functional status were obtained from patients at baseline. Medical records were accessed for data regarding co-morbidities, medications, and mortality. Propensity- score analysiswas used to balance co-variates because of the observational nature of CSB use, given this was a post hoc analysis. A multivariate Cox proportional hazards model was used to compare survival between diabetic and non-diabetic patients stratified by whether they were or were not receiving CSB therapy. Results: Of the 412 evaluable patients, 222 (54%) had diabetes and 212 (51%) were taking a CSB. At 5-year follow-up, 186 (45%) patients had died. In the multivariate analysis, using propensity scores to balance covariates, CSB therapy was an independent predictor of survival in patients without diabetes (hazard ratio 0.60; p = 0.054) only. Conclusions: These results extend prior observations that patients with diabetes andCHFmay not accrue the same mortality benefit from CSB therapy as patients without diabetes, and warrant further prospective investigation.

AB - Background: The relative benefits of cardioselective β-adrenoceptor antagonists (CSB) among patients with congestive heart failure (CHF) and diabetes mellitus are not firmly established. Objective: To determine whether diabetic patients with CHF accrue the same mortality benefit from CSB therapy as non-diabetic patients. Methods: Between October 1999 and November 2000 consecutive patients with CHF at the Veteran?s Affairs Medical Center in Indianapolis, IN, USA, were enrolled in a randomized controlled trial and prospectively followed for 5 years. Disease severity and CHF-specific functional status were obtained from patients at baseline. Medical records were accessed for data regarding co-morbidities, medications, and mortality. Propensity- score analysiswas used to balance co-variates because of the observational nature of CSB use, given this was a post hoc analysis. A multivariate Cox proportional hazards model was used to compare survival between diabetic and non-diabetic patients stratified by whether they were or were not receiving CSB therapy. Results: Of the 412 evaluable patients, 222 (54%) had diabetes and 212 (51%) were taking a CSB. At 5-year follow-up, 186 (45%) patients had died. In the multivariate analysis, using propensity scores to balance covariates, CSB therapy was an independent predictor of survival in patients without diabetes (hazard ratio 0.60; p = 0.054) only. Conclusions: These results extend prior observations that patients with diabetes andCHFmay not accrue the same mortality benefit from CSB therapy as patients without diabetes, and warrant further prospective investigation.

UR - http://www.scopus.com/inward/record.url?scp=70349149848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349149848&partnerID=8YFLogxK

U2 - 10.2165/1006180-000000000-00000

DO - 10.2165/1006180-000000000-00000

M3 - Article

C2 - 19655818

AN - SCOPUS:70349149848

VL - 9

SP - 231

EP - 240

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

IS - 4

ER -